Ilika's First Electrode Delivery Says Something Important About Ilika Stock

Why the first Stereax electrode delivery matters

The key shift at Ilika is practical, not promotional. The company has delivered its first commercial grade Stereax electrode to Cirtec for Stereax M300 production, and that shipment was its first revenue-generating order from Cirtec. That does not prove scale, but it does show the product has moved from concept into an actual manufacturing workflow.

From there, the setup is straightforward. Bulls see the start of a real feedback loop: the electrodes are intended for validation and customer sampling, which is how a niche battery business turns interest into orders. Bears are right to note that one delivery is still one delivery, and testing can run slow.

That is why the next milestones matter. Ilika expects initial royalties are anticipated in the 2027 financial year as customer testing ramps. If that timeline holds, the story can start to shift from technical progress to earning power. If it slips, the market will keep treating this as an early-stage commercial setup.

One delivery is progress, but the revenue base is still small

The delivery matters because it shows Ilika is no longer just running lab demos. The harder question for investors is whether it looks like a business yet. On that score, the answer is still no.

Revenue is still mostly grant-backed

For the year to April 2026, total revenue was flat at £1.1 million, with about £100,000 from initial Stereax sales and roughly £1 million from grants. That split captures the situation: grants are still doing most of the supporting work, while customer revenue is the part that could eventually change how the stock is judged.

The operating numbers tell the same story. Adjusted EBITDA loss widened to £6.2 million from £5.2 million, and cash and longer-term deposits fell to £5.3 million from £8.0 million. In plain English, Ilika is spending more to ramp production before that spending is being offset by meaningful sales.

The cash bridge buys time, not proof

This is where the new funding matters. Ilika has about £4.2 million of recent funding plus another £5 million raised after year-end. Part of that cash is aimed where it should be: up to £2 million for Stereax product optimisation, testing and validation, and about £3 million for Goliath. That should keep both programmes moving, but only if the spending starts to produce repeatable customer traction rather than more development activity.

Stereax still looks cleaner than Goliath in the near term

With cash under pressure, the next question is which program investors should trust first.

Why Stereax is the easier near-term thesis

For near-term execution, Stereax looks cleaner because the commercial setup is more concrete. Ilika has a 10-year licensing agreement with Cirtec Medical, is working with 16 prospective Stereax customers, and expects to recognise product revenue under that Cirtec licensing setup rather than relying on one-off sample sales. That is a more underwriteable setup than chasing distant model-year launches.

Goliath remains the bigger moonshot, and that matters. Ilika has begun shipping its 10Ah Goliath battery prototypes, and those cells were made on an automated pilot line that achieved a 93% manufacturing success rate. That is strong evidence the technology is moving out of the lab, but prototype deliveries are not the same as a repeatable revenue engine.

Where the two programs fit in the bull case

Bulls can argue the two programs serve different jobs. Stereax looks closer to licensing, customer testing, and early cash back. Goliath remains the higher-upside optionality piece. The technical case is still interesting: outside analysis suggests the technology could support 20% battery pack weight reduction and about £2,500 per vehicle in pack-level benefit. If validation stays on track, that is enough to keep interest alive.

The more important near-term shift is that management is also steering early Goliath demand toward non-EV markets, with progress in the defence industry and partnerships tied to e-bikes and Brompton. That path could offer lighter sales cycles and quicker proof of value than EV programs alone.

My read is simple: judge the stock first on Stereax execution. If that holds, Goliath becomes upside on top of a more credible commercial base.

What to watch next in Ilika's commercialization story

This is where the stock stops being a one-off headline and starts being a watchlist name.

Base-case stance

A watchful hold still makes sense. The latest funding buys time, but the market will soon want evidence that spending is turning into repeatable commercial traction rather than just more development activity following the recent funding round.

Best bull signals

Stereax - initial royalties are anticipated as the M300 moves into customer testing programmes. - Ilika is still working with 16 prospective Stereax customers. - The handoff looks operational, not theoretical, with commercial-grade electrodes already delivered for production support.

Goliath - The cleaner sign would be early wins in the defence industry or further traction via Brompton, where non-EV opportunities are already opening. - Management has also targeted initial battery sales during the current year; hitting that would shorten the path to real cash back.

What would weaken the setup

The setup gets weaker if customer feedback stays vague, royalty timing slips again, or spending continues to run ahead of repeat orders. At that point, the story goes back to being mainly about technical progress rather than a business producing visible customer revenue.